Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 4
Submit an article Journal homepage
514
Views
24
CrossRef citations to date
0
Altmetric
Letters to the Editor

Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia

Leslie A. AndritsosDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA; Correspondence[email protected]
,
Nicole R. GrieselhuberDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;
,
Mirela AnghelinaDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;
,
Kerry A. RogersDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;
,
Sameek RoychowdhuryDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;
,
Julie W. ReeserDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;
,
Cynthia D. TimmersDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;
,
Aharon G. FreudDepartment of Pathology, The Ohio State University, Columbus, OH, USA
,
James S. BlachlyDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;
,
David M. LucasDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;
,
Gerard LozanskiDepartment of Pathology, The Ohio State University, Columbus, OH, USA
,
Jeffrey A. JonesDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;
,
Katie WilliamsDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;
,
Christopher OakesDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;
,
Dan JonesDepartment of Pathology, The Ohio State University, Columbus, OH, USA
&
Michael R. GreverDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;
show all
Pages 1008-1011 | Received 06 Mar 2017, Accepted 29 Jul 2017, Published online: 18 Sep 2017

References

  • Robak T. Management of hairy cell leukemia variant. Leuk Lymphoma. 2011;52 Suppl 2:53–56.
  • Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305–2315.
  • Hockley SL, Morgan GJ, Leone PE, et al. High-resolution genomic profiling in hairy cell leukemia-variant compared with typical hairy cell leukemia. Leukemia. 2011;25:1189–1192.
  • Arons E, Suntum T, Stetler-Stevenson M, et al. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood. 2009;114:4687–4695.
  • Waterfall JJ, Arons E, Walker RL, et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet. 2014;46:8–10.
  • Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res. 2011;17:989–1000.
  • Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68:5524–5528.
  • Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007;13:1576–1583.
  • Zhao Z, Xie L, Bourne PE. Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome. PLoS One. 2017;12:e0179936.
  • Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106:20411–20416.
  • Gannon HS, Kaplan N, Tsherniak A, et al. Identification of an “Exceptional Responder” cell line to MEK1 inhibition: clinical implications for MEK-targeted therapy. Mol Cancer Res. 2016;14:207–215.
  • Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6:154–165.
  • Carlino MS, Gowrishankar K, Saunders CA, et al. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. Mol Cancer Ther. 2013;12:1332–1342.
  • Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1:80–87.
  • Tiacci E, Park JH, De Carolis L, et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015;373:1733–1747.
  • Dietrich S, Glimm H, Andrulis M, et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366:2038–2040.
  • Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:773–781.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.